Abstract

BackgroundThe Kingdom of Saudi Arabia (KSA) was the fourth country in the world to authorize the BNT162b2 coronavirus disease 2019 (COVID-19) vaccine, which it rolled out on December 17, 2020 and first targeted at healthcare workers (HCWs). This study assesses vaccine uptake among this group during the first month of its availability. MethodsA national cross-sectional, pilot-validated, self-administered survey was conducted among HCWs in the KSA between December 27, 2020 and January 3, 2021. The survey included sociodemographic details, previous contact with COVID-19 patients, previous infection with COVID-19, receiving (or registering with the Ministry of Health website to receive) the COVID-19 vaccine, sources of HCWs’ information on vaccines, awareness of emerging variants of concern, and anxiety level using the 7-item Generalized Anxiety Disorder assessment. A descriptive bivariate analysis and multivariate logistic binary regression analysis were performed. The primary evaluated outcome was vaccine uptake. ResultsOf the 1058 participants who completed the survey, 704 (66.5%) were female, and 626 (59.2%) were nurses. Of all the respondents, 352 (33.27%) were enrolled to receive or had already received the vaccine, while 706 (66.73%) had not enrolled. In a bivariate analysis, not enrolling for vaccination was more likely in females than males (78.5% vs. 21.5%, P < 0.001), HCWs between the ages of 20 and 40 years than those >40 years (70.4% vs. 29.6%, P = 0.005), Saudi HCWs than expatriates (78% vs 22%, P < 0.001), and among HCWs who used social media as a source of information than those who did not (69.8% vs. 38.6%, P < 0.001). In a multivariate analysis, independent factors associated with uptake were being a Saudi national (aOR = 1.918, 95 %CI = 1.363–2.698, P < 0.001), working in an intensive care unit (aOR = 1.495, 95 %CI = 1.083–2.063, P = 0.014), and working at a university hospital (aOR = 1.867, 95 %CI = 1.380–2.525, P < 0.001). ConclusionsA low level of vaccine uptake was observed especially in female HCWs, those younger than 40 years old, and those who used social media as their source of vaccine information. This survey provides important information for public health authorities in order to scale up vaccination campaigns targeting these HCWs to increase vaccine enrollment and uptake.

Highlights

  • After the coronavirus disease 2019 (COVID-19) reached pandemic levels, vaccine development was fast tracked through government funding, corporate spending, and private donations [1]

  • The first case of COVID-19 in Kingdom of Saudi Arabia (KSA) was detected on March 2, 2020, and as of December 28, 2020, a total of 362,972 laboratory-confirmed cases were reported with 6239 deaths [10]

  • The KSA granted Pfizer/BioNTech emergency use authorization for the BNT162b2 vaccine on December 10, 2020, becoming the fourth country to do so after the United Kingdom (UK) that approved it December 2, Bahrain December 4, and Canada December 9, 2020 [11,12], As of January 3, 2021, at least one dose of vaccine was given to 1,380,430 individuals in UK, 60,097 in Bahrain, and 114,034 in Canada, no data was reported on healthcare workers (HCWs) [13]

Read more

Summary

Introduction

After the coronavirus disease 2019 (COVID-19) reached pandemic levels, vaccine development was fast tracked through government funding, corporate spending, and private donations [1]. In an earlier study from the Kingdom of Saudi Arabia (KSA), 70% of the 1521 HCWs surveyed were willing to receive the COVID-19 vaccine [6]. Another study showed that 63% of the nurses surveyed were willing to receive the COVID-19 vaccine [6,7]. This study was conducted to evaluate vaccine enrollment and uptake within the first month of its rollout among HCWs in the KSA. The Kingdom of Saudi Arabia (KSA) was the fourth country in the world to authorize the BNT162b2 coronavirus disease 2019 (COVID-19) vaccine, which it rolled out on December 17, 2020 and first targeted at healthcare workers (HCWs).

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call